Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors.
Radiolabeled peptides have become important tools in nuclear oncology, both as diagnostics and more recently also as therapeutics. They represent a distinct sector of the molecular targeting approach, which in many areas of therapy will implement the old "magic bullet" concept by specifically directing the therapeutic agent to the site of action. In this three-part review, we present a comprehensive overview of the literature on receptor-mediated tumor targeting with the different radiopeptides currently studied. Part I summarizes the general concepts and methods of targeting, the selection of radioisotopes, chelators, and the criteria of peptide ligand development. Then, the >400 studies on the application to somatostatin/somatostatin-release inhibiting factor receptor-mediated tumor localization and treatment will be reviewed, demonstrating that peptide radiopharmaceuticals have gained an important position in clinical medicine.
Eberle
Alex N
AN
Laboratory of Endocrinology, Department of Research, University Hospital and University Children's Hospital, Basel, Switzerland. Alex-N.Eberle@unibas.ch
Mild
Gabriele
G
Froidevaux
Sylvie
S
D000818:Animals; D002614:Chelating Agents / Q000494:pharmacology; D006801:Humans; D008024:Ligands; D008954:Models, Biological; D008956:Models, Chemical; D009369:Neoplasms / Q000532:radiotherapy*; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology*; D011868:Radioisotopes / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000494:pharmacology*; D017481:Receptors, Somatostatin / Q000096:biosynthesis*; D013004:Somatostatin / Q000378:metabolism
D002614:Chelating Agents; D008024:Ligands; D010455:Peptides; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D013004:Somatostatin